.jpg "Fatih Uckun, MD, PhD photo")
Oncotelic Therapeutics
Agoura Hills, United States
Fatih Uckun, MD, PhD is the Chief Medical Officer of Oncotelic/Mateon Therapeutics. Dr. Uckun is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO and AACR. He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals. Dr. Uckun worked as a Professor of Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota (1986-1997), where he became the first recipient of the Endowed Hughes Chair in Biotherapy, and as a Professor of Pediatrics and Head of Translational Research in Leukemia and Lymphoma of the Children’s Center for Cancer and Blood Diseases at the University of Southern California (2009-2015). Dr. Uckun also served as the Chair of the Biotargeting Working Group of the NCI Alliance for Nanotechnology in Cancer (2010-2016). He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and authored numerous review articles as well book chapters. He received numerous awards including the Clinical Scholar Award as well as the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar, the Academy Science Prizes of TUBA and TUBITAK, and the Research Award of the Radiation Research Society. He has served as a member of several medical journal editorial boards and NIH/ACS grant review/special emphasis panels.